Alector, Inc. insider trading
Every open-market purchase and sale by Alector, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Alector, Inc.’s insiders pay?
From August 9, 2019 to September 4, 2026, 12 insiders reported 1 open-market purchase and 65 sales not made under a pre-set plan in Alector, Inc. Twelve months after each purchase was reported, the shares were −54.2% against the S&P 500 on average (median −54.2%), over 1 purchase with a full year of prices; 0% beat the index. After sales, the shares moved −61.2% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 4, 2020 into $8,241 by November 2, 2026, −2.8% a year. It held shares 15% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $14,590 (+5.8% a year), and held throughout $25,283 (+14.8%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Rosenthal Arnon | Chief Executive Officer | 0 | — | — | 16 | −58.3% (6) | September 4, 2026 |
| Kenkare-Mitra Sara | President and Head of R&D | 0 | — | — | 12 | −63.4% (5) | December 3, 2025 |
| Romano Gary | Chief Medical Officer | 0 | — | — | 10 | −63.0% (6) | March 5, 2025 |
| Grasso Marc | Chief Financial Officer | 0 | — | — | 8 | −72.9% (3) | June 4, 2025 |
| Orbimed Advisors LLC | 10% owner | 0 | — | — | 7 | −64.4% (7) | April 16, 2020 |
| Berkley Neil Lindsay | CFO & Chief Business Officer | 0 | — | — | 5 | — | September 4, 2026 |
| Mcguire Terrance | Director | 0 | — | — | 2 | −48.0% (2) | September 13, 2023 |
| Wong-Sarad Grace | Principal Accounting Officer | 0 | — | — | 2 | — | March 3, 2026 |
| Orbimed Capital Gp IV LLC | 10% owner | 0 | — | — | 1 | −40.6% (1) | August 9, 2019 |
| Orbimed Capital LLC | 10% owner | 0 | — | — | 1 | −35.2% (1) | January 13, 2020 |
| Scheller Richard H | Director | 0 | — | — | 1 | −72.5% (1) | August 23, 2024 |
| Wehner David M. | Director | 1 | −54.2% (1) | 0% | 0 | — | February 3, 2020 |
When several insiders traded Alector, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Alector, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 2 selling crowds, −32.0%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| March 31, 2023 | 4 selling | −11.4% | −5.1% | −33.6% |
| June 30, 2020 | 3 selling | −64.0% | −58.9% | −55.7% |